Sites of GVHD involvement. (A) The bar graph displays the percentage of all evaluable patients with specified organ involvement at baseline: 94% of patients had skin cGVHD involvement at baseline. (B) The bar graph displays the percentage of all evaluable patients with site-specific clinical improvement after 6 abatacept infusion: 42% of patients experienced improvement in mouth cGVHD after exposure to abatacept.